A Phase 3 interventional study of pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 84 Years. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 6 in phase 3, and was the 4th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,058 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one has the largest enrollment of the 24 interventional ones that give a count, is the only one that started in 2008, is one of 11 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2000.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.
This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. Eligible patients must complete the final visit for their qualifying study, have not permanently discontinued study drug in their qualifying study, and meet all of the eligibility criteria noted in this protocol.
Since data from the qualifying study may remain blinded during patient enrollment in PIPF-012, all patients will be treated as if they were taking placebo in their qualifying study. At the start of PIPF-012 participation, each patient will escalate the dose of pirfenidone.
The duration of treatment for each patient will vary and will continue until pirfenidone is commercially or otherwise available in his/her geographic region or the study is terminated by the sponsor for reasons outlined in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pirfenidone
Drug: pirfenidone
Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
Percentage of Participants With Adverse Events
An adverse event defined as any unfavorable, harmful, or pathologic change in a research participant administered a pharmaceutical study treatment as indicated by physical signs, symptoms, and/or clinically significant laboratory abnormalities that occurred during the treatment and the post-treatment period, regardless of suspected cause.
Time frame: 7.5 years
| Milestone | Pirfenidone |
|---|---|
| Started | 1058 |
| Completed | 427 |
| Not completed | 631 |
| Withdrew: Reason not specified | 3 |
| Withdrew: Withdrawn consent | 22 |
| Withdrew: Withdrawal by subject | 83 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Physician decision | 19 |
| Withdrew: Lung transplantation | 44 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 95 |
| Withdrew: Adverse event | 358 |
| Withdrew: Continued treatment | 5 |
An adverse event defined as any unfavorable, harmful, or pathologic change in a research participant administered a pharmaceutical study treatment as indicated by physical signs, symptoms, and/or clinically significant laboratory abnormalities that occurred during the treatment and the post-treatment period, regardless of suspected cause.
| percentage of participants | Pirfenidone |
|---|---|
| Percentage of Participants With Adverse Events | 98.0 |
Collected over 7.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone | — | 571/1,058 (54%) | 1,027/1,058 (97.1%) |
| Event | Pirfenidone |
|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 230/1058 |
| PneumoniaInfections and infestations | 90/1058 |
| BronchitisInfections and infestations | 32/1058 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 30/1058 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 29/1058 |
| Atrial fibrillationCardiac disorders | 26/1058 |
| Coronary artery diseaseCardiac disorders | 20/1058 |
| SyncopeNervous system disorders | 20/1058 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 19/1058 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 17/1058 |
| Event | Pirfenidone |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 330/1058 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 325/1058 |
| NauseaGastrointestinal disorders | 305/1058 |
| Upper respiratory tract infectionInfections and infestations | 295/1058 |
| BronchitisInfections and infestations | 254/1058 |
| DiarrhoeaGastrointestinal disorders | 242/1058 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 221/1058 |
| FatigueGeneral disorders | 210/1058 |
| NasopharyngitisInfections and infestations | 202/1058 |
| DizzinessNervous system disorders | 176/1058 |
All treated participants
| Age, Continuous(years) | Pirfenidone |
|---|---|
| Mean | 68.5 ± 7.47 |
| Sex: Female, Male(Participants) | Pirfenidone |
|---|---|
| Female | 268 |
| Male | 790 |
The record gives a start of Aug 2008, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
Idiopathic Pulmonary Fibrosis →